2017 INDUCTEE Michael Hayden, MD PhD Cells, Genetics & Genomics

Michael Hayden inducted into the Canadian Medical Hall of Fame

Quebec City, Quebec

Dr. Hayden was recognized as one of the 100 Most Inspiring People in the Pharmaceutical Industry by Pharmavoice

Dr. Hayden became the Director of the Translational Laboratory in Genetic Medicine in Singapore

The following year he began serving as President of Global R &D and Chief Scientific Officer of Teva Pharmaceuticals headquartered in Israel.

Along with Dr. Bruce Carleton, Dr. Hayden created Genotype-Specific Approaches to Therapy in Childhood

This revolutionary network brings together experts from across many institutions and disciplines.

Learning from the success of the South Africa Clinic, Dr. Hayden founded BC’s first Huntington’s Disease Clinic

Dr. Hayden served as Editor-in-Chief of Clinical Genetics until 2015

As part of an effort to translate scientific discoveries into commercial products, Dr. Hayden established NeuroVir Pharmaceutic

In 1997 and 2001, he also founded Xenon Genetics, Inc. and Aspreva Pharmaceuticals Inc.

For 19 years, Dr. Hayden served as the Director of the Centre for Molecular Medicine and Therapeutics in Vancouver

To facilitate increased scientific collaboration, Dr. Hayden established the Canadian Collaborative Network on Predictive Testing for Huntington's Disease

He later established two other research networks: the Canadian Genetics Disease Network and the Canadian Pharmacogenomics Network for Drug Safety.

BC’s first annual summer camp for Huntington’s Disease patients was established by Dr. Hayden

Dr. Hayden came to Canada and joined the medical faculty at the University of British Columbia

Dr. Michael Hayden established the 1st Huntington’s Disease Clinic in South Africa

The clinic was the first of its kind in Africa.

Medical Student Charles Oscar Waters authored the first description of Huntington’s Disease (HD)